Loading clinical trials...

A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD | Clinical Trials | Clareo Health

RECRUITING

A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD

CMR Substudy of Coronary Sinus Reducer for the Management of Symptomatic Heart Failure With a Preserved Ejection Fraction (HFpEF) Associated With Coronary Microvascular Dysfunction (CMD)

NCT07093528•Mayo Clinic

View on ClinicalTrials.gov

Summary

To evaluate the effect of CS reducer implantation in patients with HFPEF and CMD on myocardial ischemia, measured by stress myocardial perfusion using cardiovascular magnetic resonance (CMR)

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age ≥18
•Enrollment in main CS-reducer HFPEF study IRB# 25-002292

Exclusion Criteria

•Metal implants that are not suitable for MRI
•Inability or unwillingness of individual to give written informed consent.

Locations (1)

Mayo Clinic

Rochester, Minnesota, United States

Key Dates

Start Date

October 16, 2025

Primary Completion Date

August 1, 2027

Completion Date

August 1, 2027

Last Updated

February 27, 2026

Enrollment

ESTIMATED participants

Conditions

Heart Failure With Preserved Ejection FractionCoronary Microvascular Dysfunction

Interventions

Cardiovascular Magnetic Resonance (CMR)

DIAGNOSTIC_TEST

Contacts

Diana Albers

CONTACT

507-255-6884 albers.diana2@mayo.edu

Prospective Evaluation of AI-ECG for SHD Detection

NCT07057466

Valvular Heart Disease Stenosis and Regurgitation (Diagnosis)Pulmonary Hypertension (Diagnosis)+2 more

View study

RECRUITINGPHASE1

A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT07219511

HeartHeart Failure With Preserved Ejection Fraction (HFPEF)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 27, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD

Inclusion Criteria

Exclusion Criteria

Prospective Evaluation of AI-ECG for SHD Detection

A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication

Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction

Assessment of CCM in HF With Higher Ejection Fraction

Tailored Exercise Training Study Among Adults With HFpEF